January 4, 2023

HIROTSU BIO SCIENCE INC.


High Demand for Pre-Orders of New Service!!

World's First Early Pancreatic Cancer Test "N-NOSE® plus Pancreas"

－Official Launch this January－

HIROTSU BIO SCIENCE INC. (Head Office: Chiyoda-ku, Tokyo; Representative; Takaaki Hirotsu (Hereinafter referred to as “HIROTSU”)), will start the actual testing of the world's first early pancreatic cancer test "N-NOSE plus Pancreas," developed as the first test of the next-generation "cancer type-specific test" derived from the nematode cancer test "N-NOSE." We have received more applications than expected during the approximately one-month pre-order period, reflecting our customers' strong desire for early detection of pancreatic cancer. Our company remains committed to research and development to create a future where cancer is no longer feared, and to provide reassurance to many through high-precision testing.

Our company has succeeded in developing "N-NOSE plus Pancreas," the first next-generation "cancer type-specific" test of "N-NOSE®" primary cancer screening, and will begin actual testing this year. "Pancreatic cancer" is considered the most difficult to detect and treat among cancers, and the medical community has regarded the development of an early pancreatic cancer test as revolutionary. By leveraging the excellent capabilities of biological organisms and the fusion of biotechnology, we aim to use this test to save as many lives as possible.



■Overview of "N-NOSE plus Pancreas"

Testing Start (Test Kit Shipment): From January 4, 2023 (Wednesday)
Sales Website: https://lp.n-nose.com/suizou/
Testing Fee: Regular price ¥70,000 (including tax). For those who have taken "N-NOSE®" within three months, the price is ¥50,000 (including tax).

■About HIROTSU BIO SCIENCE

We as HIROTSU aim to protect the health and future security of people through research, development, and practical application of unique technology that utilize the capabilities of living organisms. Established in 2016, N-NOSE was put into practical use thanks to our researchers` abundance of ideas and tireless efforts. Despite the importance of extending healthy life expectancy being emphasized, it is said that one in every two people will be diagnosed with cancer in this age of 100-year life expectancy. We strive to contribute to solving these social issues with our groundbreaking “bio-diagnoses” technology that utilizes the power of nematodes.

Company Name: HIROTSU BIO SCIENCE INC.
Headquarters: 22F New Otani Garden Court, 4-1 Kioi-cho, Chiyoda-ku, Tokyo
Representative: Takaaki Hirotsu, CEO
Date of Establishment: August 2016

Main Service: Research, development, and marketing of cancer screenings using nematodes and nematode olfactory sensors.
Official Website: https://hbio.jp/en/

■ About “N-NOSE”

A primary screening test for cancer that utilizes the highly accurate detection of cancer-specific odors in human urine by the nematode *C. elegans*, which has a very good sense of smell. By simply submitting urine, the test is simple, inexpensive, highly accurate, and provides a whole-body comprehensive examination of early-stage cancer risk.
Official Service Website: https://lp.n-nose.com/

■ About “N-NOSE plus Pancreas”

N-NOSE's next-generation "Cancer Type Specific Test". This test uses a "special nematode" genetically engineered from the nematode *C. elegans* that specifically reacts only to the smell of pancreatic cancer. This "special nematode" has a high ability to distinguish between pancreatic cancer and other cancers, enabling non-invasive detection of early-stage pancreatic cancer.
Official Service Website: https://lp.n-nose.com/suizou/

Press Contact
HIROTSU Bio Science PR
E-mail：press@hbio.jp